Repare Therapeutics Inc
Repare Therapeutics Inc (RPTX) is a clinical-stage precision oncology company developing small-molecule therapies that target DNA damage response pathways and exploit synthetic lethality to preferentially affect tumour cells. Its pipeline comprises development programmes designed to sensitize cancers to existing treatments or to target tumour-specific repair defects. As a small-cap biotech (market cap roughly $81m), the company’s valuation is heavily influenced by clinical trial readouts, regulatory milestones and financing events. Investors should expect higher volatility, potential dilution from future fundraising and binary outcomes tied to trial results. Liquidity can be limited and share-price swings pronounced. This summary is for educational purposes only and not personalised advice; biotech investments carry high risk and past performance is not a reliable indicator of future returns.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Repare Therapeutics' stock with a target price of $9.6, indicating strong potential growth.
Financial Health
Repare Therapeutics is generating solid revenue and cash flow, indicating a healthy financial position.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring RPTX
Beyond Vaccines: The mRNA Revolution
BioNTech's strong vaccine sales are fueling its expansion into new medical fields, particularly cancer treatment. This strategic shift highlights a broader investment opportunity in companies pioneering the next wave of mRNA-based therapies.
Published: August 5, 2025
Explore BasketPharma's Next Big Deal
This carefully curated group of stocks features promising biotech companies with valuable drug pipelines. These smaller firms could become the next targets for lucrative partnerships or acquisitions by pharmaceutical giants, similar to Glenmark's recent $2 billion deal with AbbVie.
Published: July 11, 2025
Explore BasketAge-Reversal Biotech
Invest in pioneering companies that are redefining aging as a treatable condition. These carefully selected biotechs are developing groundbreaking therapies to extend healthy lifespans and potentially reverse cellular damage, creating an entirely new frontier in medicine.
Published: June 17, 2025
Explore BasketGarage Innovators
Meet the companies that are inventing tomorrow, today. These stocks represent businesses with exceptional in-house research and development, carefully selected by professional analysts for their ability to create breakthrough products and technologies from within.
Published: June 17, 2025
Explore BasketWhy You’ll Want to Watch This Stock
DNA repair focus
Repare’s programmes aim at DNA damage response and synthetic lethality, a concept that can produce targeted cancer effects — though clinical proof is required and outcomes vary.
Clinical catalysts ahead
Trial readouts and regulatory milestones can materially move the share price, offering opportunity but also binary risk depending on results.
Small-cap dynamics
With a modest market cap and limited liquidity, the stock can be volatile and subject to dilution from future fundraising; suitable for risk-tolerant investors.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
ACADIA Pharmaceuticals Inc.
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of treatments for central nervous system disorders.
ARCELLX, INC.
Develops T-cell therapies for the treatment of cancer.
AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company that provides technology to discover and develop novel fully human monoclonal antibodies.
